Treatment Naïve Wet AMD

Sponsor: EyePoint – Lugano

In this trial, we are investigating the safety and efficacy of the Vorolanib implant in the treatment of wet macular degeneration. Vorolanib is a multiple kinase inhibitor that works slightly downstream in the angiogenesis pathway compared to current anti-VEGF therapies. It is a sustained-release implant that is injected into the eye in a similar fashion to our traditional injection therapies. It is unique in that rather than injecting a liquid medication in the eye, Vorolanib is injected as a dissolvable pellet that slowly releases the medication over several months. Previous studies have shown that Vorolanib injections are safe and can significantly reduce the number of regular anti-VEGF injections patients may need afterwards. Many patients remained injection-free for the duration of the study after a single implant. In this trial, we are recruiting patients with newly diagnosed wet macular degeneration. They will be split into two groups, with 1 receiving a Vorolanib implant and the other receiving Eylea injections. The study will be conducted over a 2 year period. At any point in the study, if a patient is not responding well to therapy and meets rescue criteria, they will be treated with standard of care treatment. We hope this trial will be able to demonstrate that Vorolanib can have a long-lasting effect in the eye and reduce the need for repeated anti-VEGF injections.

For more information, visit luganoclinicaltrial.com or connect with one of our clinical coordinators.